Avacta Group (LON:AVCT) Hits New 1-Year High – What’s Next?

Shares of Avacta Group Plc (LON:AVCT) reached a new 52-week high on Wednesday . The stock traded as high as GBX 78.83 and last traded at GBX 77.60, with a volume of 5730924 shares. The stock had previously closed at GBX 73.20.

Wall Street Analyst Weigh In

Separately, Peel Hunt reissued a “buy” rating and set a GBX 99 target price on shares of Avacta Group in a research note on Monday, October 13th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of GBX 99.

Avacta Group Trading Up 6.0%

The company has a debt-to-equity ratio of 52.53, a current ratio of 1.29 and a quick ratio of 4.96. The business has a fifty day moving average of GBX 62.98 and a 200-day moving average of GBX 46.94. The stock has a market capitalization of £316.82 million, a price-to-earnings ratio of -4.42 and a beta of 1.12.

Avacta Group (LON:AVCT) last issued its quarterly earnings results on Tuesday, September 30th. The biotechnology company reported GBX (4.46) earnings per share for the quarter. Avacta Group had a negative net margin of 114.45% and a negative return on equity of 74.00%. On average, equities analysts anticipate that Avacta Group Plc will post -9.9011833 earnings per share for the current fiscal year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).